A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...
Among patients with late diagnosed HIV infection, the choice of a two- or three-drug regimen is not associated with 48 week ...
More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...
ScienceAlert on MSN
HIV's Cunning Strategy For Hiding in Our Body Finally Revealed
According to the new study, HIV achieves this with a tissue-specific approach, cloaking itself in a host cell's DNA by ...
In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly powerful antibody, called 04_A06, that is able to neutralize nearly all of the ...
Currently available medications could be enough to end the HIV epidemic in the United States, provided people can access and ...
The American South has the highest HIV rates in the country, accounting for more than half of new HIV diagnoses nationwide in ...
Gilead Sciences (NASDAQ:GILD) has discontinued a Phase 1 trial for GS-1219, a long-acting subcutaneously delivered treatment ...
Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...
South Africa has welcomed a U.S. bridging plan worth $115 million to continue funding HIV treatment and prevention programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback